Literature DB >> 15831601

Pathophysiology of heart failure following myocardial infarction.

A D Struthers1.   

Abstract

The structural and functional abnormalities that lead to cardiac death are coronary artery disease and left ventricular abnormalities related to remodelling (left ventricular hypertrophy, left ventricular systolic dysfunction, and left ventricular fibrosis). Aldosterone adversely affects all of these processes. It produces both a vasculopathy and left ventricular dysfunction and fibrosis. Endothelial dysfunction in the coronary arteries can lead to acute coronary events. Left ventricular dysfunction will cause the progression of heart failure, and left ventricular fibrosis and dysfunction provide an arrhythmic substrate. The combination of acute coronary events and arrhythmias can lead to sudden cardiac deaths, while acceleration of the heart failure disease process can lead to deaths from progressive heart failure. The increased understanding of the mechanistic role of aldosterone in cardiovascular disease provides a rationale for the positive results that have been seen in clinical trials of aldosterone blockade.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15831601      PMCID: PMC1876343          DOI: 10.1136/hrt.2005.062034

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  17 in total

1.  Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure.

Authors:  George Suzuki; Hideaki Morita; Takayuki Mishima; Victor G Sharov; Anastassia Todor; Elaine J Tanhehco; Amy E Rudolph; Ellen G McMahon; Sidney Goldstein; Hani N Sabbah
Journal:  Circulation       Date:  2002-12-03       Impact factor: 29.690

2.  Aldosterone induces a vascular inflammatory phenotype in the rat heart.

Authors:  Ricardo Rocha; Amy E Rudolph; Gregory E Frierdich; Denise A Nachowiak; Beverly K Kekec; Eric A G Blomme; Ellen G McMahon; John A Delyani
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-11       Impact factor: 4.733

3.  Mineralocorticoid receptor antagonism in experimental atherosclerosis.

Authors:  Sanjay Rajagopalan; Damon Duquaine; Steven King; Bertram Pitt; Paresh Patel
Journal:  Circulation       Date:  2002-05-07       Impact factor: 29.690

4.  Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure.

Authors:  C A Farquharson; A D Struthers
Journal:  Circulation       Date:  2000-02-15       Impact factor: 29.690

Review 5.  Pathophysiological effects of aldosterone in cardiovascular tissues.

Authors:  R Rocha; C T Stier
Journal:  Trends Endocrinol Metab       Date:  2001-09       Impact factor: 12.015

6.  Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Authors:  Bertram Pitt; Willem Remme; Faiez Zannad; James Neaton; Felipe Martinez; Barbara Roniker; Richard Bittman; Steve Hurley; Jay Kleiman; Marjorie Gatlin
Journal:  N Engl J Med       Date:  2003-03-31       Impact factor: 91.245

7.  Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy.

Authors:  Colin A J Farquharson; Allan D Struthers
Journal:  Clin Sci (Lond)       Date:  2002-10       Impact factor: 6.124

8.  Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction.

Authors:  Masaru Hayashi; Takayoshi Tsutamoto; Atsuyuki Wada; Takashi Tsutsui; Chitose Ishii; Keijin Ohno; Masanori Fujii; Atsushi Taniguchi; Tomokazu Hamatani; Yoshitaka Nozato; Ken Kataoka; Naoki Morigami; Masato Ohnishi; Masahiko Kinoshita; Minoru Horie
Journal:  Circulation       Date:  2003-05-05       Impact factor: 29.690

9.  Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure.

Authors:  Mariantonietta Cicoira; Luisa Zanolla; Andrea Rossi; Giorgio Golia; Lorenzo Franceschini; Giovanna Brighetti; Paolo Marino; Piero Zardini
Journal:  J Am Coll Cardiol       Date:  2002-07-17       Impact factor: 24.094

10.  Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment.

Authors:  J E Macdonald; N Kennedy; A D Struthers
Journal:  Heart       Date:  2004-07       Impact factor: 5.994

View more
  10 in total

1.  Engineering a naturally-derived adhesive and conductive cardiopatch.

Authors:  Brian W Walker; Roberto Portillo Lara; Chu Hsiang Yu; Ehsan Shirzaei Sani; William Kimball; Shannon Joyce; Nasim Annabi
Journal:  Biomaterials       Date:  2019-03-21       Impact factor: 12.479

Review 2.  Injectable Hydrogels for Cardiac Tissue Engineering.

Authors:  Brisa Peña; Melissa Laughter; Susan Jett; Teisha J Rowland; Matthew R G Taylor; Luisa Mestroni; Daewon Park
Journal:  Macromol Biosci       Date:  2018-05-07       Impact factor: 4.979

3.  The impact of pressure overload on coronary vascular changes following myocardial infarction in rats.

Authors:  Jiqiu Chen; Artiom Petrov; Elisa Yaniz-Galende; Lifan Liang; Hans J de Haas; Jagat Narula; Roger J Hajjar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-12-28       Impact factor: 4.733

4.  Post-translational regulation of a hypoxia-responsive VEGF plasmid for the treatment of myocardial ischemia.

Authors:  Young-Wook Won; Arlo N McGinn; Minhyung Lee; Kihoon Nam; David A Bull; Sung Wan Kim
Journal:  Biomaterials       Date:  2013-05-25       Impact factor: 12.479

Review 5.  Senescent cells: a therapeutic target for cardiovascular disease.

Authors:  Bennett G Childs; Hu Li; Jan M van Deursen
Journal:  J Clin Invest       Date:  2018-04-02       Impact factor: 14.808

6.  Cushing's syndrome patient who exhibited congestive heart failure.

Authors:  L Petramala; P Battisti; G Lauri; L Palleschi; D Cotesta; M Iorio; G De Toma; S Sciomer; C Letizia
Journal:  J Endocrinol Invest       Date:  2007-06       Impact factor: 4.256

Review 7.  Functional polymers of gene delivery for treatment of myocardial infarct.

Authors:  Young-Wook Won; David A Bull; Sung Wan Kim
Journal:  J Control Release       Date:  2014-07-27       Impact factor: 9.776

Review 8.  Heart-kidney crosstalk and role of humoral signaling in critical illness.

Authors:  Grazia Virzì; Sonya Day; Massimo de Cal; Giorgio Vescovo; Claudio Ronco
Journal:  Crit Care       Date:  2014-01-06       Impact factor: 9.097

9.  Diagnostic Performance of Selected Baseline Electrocardiographic Parameters for Prediction of Left Ventricular Remodeling in Patients with ST-Segment Elevation Myocardial Infarction.

Authors:  Michał Kasprzak; Tomasz Fabiszak; Marek Koziński; Jacek Kubica
Journal:  J Clin Med       Date:  2021-05-29       Impact factor: 4.241

Review 10.  Novel Therapeutic Targets for Hypoxia-Related Cardiovascular Diseases: The Role of HIF-1.

Authors:  Minxuan Liu; Gina Galli; Yilin Wang; Qiru Fan; Zhenzhong Wang; Xin Wang; Wei Xiao
Journal:  Front Physiol       Date:  2020-07-15       Impact factor: 4.566

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.